Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Building an outcome predictor model for diffuse large B-cell lymphoma.

Ana-Isabel Sáez1, Antonio-José Sáez, María-Jesús Artiga

  • 1Universidad de Granada, Spain.

The American Journal of Pathology
|January 27, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anemia and Hypoalbuminemia are Associated with Hepatic Encephalopathy and Mortality after Portal Hypertension-Related Bleeding.

Gastroenterologia y hepatologia·2026
Same author

KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm.

Blood advances·2026
Same author

The REMA Score Revisited: An Optimized Algorithm for Early Prediction of Clonal Mast Cell Disease.

Allergy·2026
Same author

MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders.

Cancer research·2026
Same author

"We have to keep moving": perspectives on the challenges and opportunities in providing mental health services for people on the move in Latin America.

Frontiers in psychiatry·2026
Same author

Development of lymphomatoid papulosis during brentuximab vedotin treatment: a paradoxical phenomenon.

Leukemia & lymphoma·2026

This study introduces a new protein-expression predictor for diffuse large B-cell lymphoma (DLBCL) outcomes. The 8-marker model accurately identifies patient prognosis, improving upon current treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Diffuse large B-cell lymphoma (DLBCL) treatment protocols are often uniform, despite significant patient variability.
  • Existing prognostic tools may not fully capture the biological complexity of DLBCL.

Purpose of the Study:

  • To develop and validate a novel protein-expression-based outcome predictor for DLBCL patients.
  • To identify key molecular markers associated with treatment response and disease progression in DLBCL.

Main Methods:

  • Analysis of 52 protein expressions using tissue microarrays (TMAs) in 152 DLBCL patients.
  • Development of a predictive model using a training set (103 patients) and validation in an independent set (49 patients).
  • Integration of the biological score with the International Prognostic Index (IPI) to enhance predictive accuracy.

Related Experiment Videos

Main Results:

  • An 8-marker predictive model achieved 78% accuracy in identifying treatment failure probability.
  • The biological score accurately stratified patients into "failure-free" (92.3%) and "fatal or refractory disease" (96.2%) groups.
  • Combining the biological score with IPI improved prediction of failure and survival.

Conclusions:

  • A protein-expression-based score offers a valuable tool for predicting DLBCL patient outcomes.
  • This predictor complements the IPI, enabling more precise patient risk stratification.
  • The findings support personalized treatment approaches for DLBCL based on molecular profiles.